Form 4: Director John Johnson Acquires Verastem Stock

Verastem, Inc. director John Johnson reported the acquisition of 36,000 shares of common stock.

Summary

• Director John Johnson acquired 36,000 shares of Verastem, Inc. common stock on May 21, 2026.
• The acquisition was made at a price of $0.00, indicating a grant or award.
• Following this transaction, Mr. Johnson beneficially owns 52,666 shares of common stock.
• The shares acquired are Restricted Stock Units (RSUs) granted under the Issuer's Amended and Restated 2021 Equity Incentive Plan.
• These RSUs vest in twelve installments, with the first eleven vesting monthly from June 2026 to April 2027, and the final installment vesting on the earlier of the day before the 2027 Annual Meeting or May 31, 2027, contingent on continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity award to a director rather than a significant change in beneficial ownership or a market-moving event.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The grant of RSUs indicates a long-term incentive structure for key personnel.
• Vesting schedule tied to continued service aligns management's interests with the company's long-term success.

Negatives

• The acquisition price of $0.00 suggests these were not open market purchases, but rather equity awards.
• The filing does not provide details on the performance metrics or conditions tied to the RSUs beyond continued service.

Risks

• The vesting of RSUs is contingent on the reporting person continuing to serve as a director, implying a risk of forfeiture if service is terminated.
• Future stock price performance will determine the ultimate value of the awarded RSUs.

Future Outlook

The vesting schedule for the RSUs extends through May 2027, indicating a long-term commitment and incentive for the director to remain with the company and contribute to its success over this period.

Industry Context

StockSavvy.ai notes that insider grants of equity, such as RSUs, are a common practice in the biotechnology and pharmaceutical sectors to attract and retain executive and director talent, aligning their financial interests with shareholder value over the long term.

Stakeholder Impact

• Shareholders: The acquisition of stock by a director, even if through an award, can be viewed positively as it aligns director interests with long-term company performance. The vesting schedule ensures continued director engagement.
• Employees: The RSU grant highlights the company's use of equity-based compensation, a common practice that can motivate and retain talent.
• Management: The award is part of the compensation structure for directors.

Next Steps

• Continued service by John Johnson as a director to meet vesting conditions for RSUs.
• Monthly vesting of RSU installments from June 2026 through April 2027.
• Final vesting of remaining RSUs on or before May 31, 2027, or the day before the 2027 Annual Meeting.

Key Dates

Keywords

Verastem, VSTM, Form 4, Insider Trading, Stock Acquisition, RSU, Equity Incentive Plan, Director Compensation, Beneficial Ownership